Manatt Health July 25, 2023
Editor’s Note: In a new white paper, summarized below, Manatt Health discusses emerging reimbursement models for cell and gene therapies. The paper provides an overview of current Medicaid, Medicare and commercial coverage, including separate payment policies, value-based payment (VBP) arrangements and reinsurance programs. Click here to download a free copy of the full white paper.
More than ten cell and gene therapies have been approved by the FDA in the past five years,1 and over 500 gene-based therapies are in clinical development2 as of 2023. Based on current pipeline and product success rates, the Food and Drug Administration (FDA) anticipates approving 10–20 a year by 2025,3 with spending expected to reach $25 billion annually over the next ten years.4 With...
Today's Sponsors
Today's Sponsor